Clinical Trials Logo
  1. Home
  2. Relapsed Non Hodgkin Lymphoma
  3. NCT06049381

Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research

Relapsed Non-Hodgkin Lymphoma Clinical Trial

Official title:
Tumor Microenvironment Mechanism of LY007 Cell Injection for the Treatment of Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma and the Exploration of Novel CAR-T Translational Research

Clinical Trial Summary

The T cell characteristics of 12 patients treated with CD20 CAR-T (LY007 cell injection) were analyzed to study their relationship with CAR-T anti-tumor activity, tumor killing, and in vivo proliferation, and to explore the mechanisms: before single harvesting, before bridging, before pretreatment, D0, D7, D14, D21, D28, and at the time of follow-up evaluation (plus time points if taking BTKi inhibitors: Peripheral blood specimens were collected before BTKi and 48h after BTKi discontinuation, and peripheral blood cells from patients before and after treatment were analyzed by mass spectrometry flow and single-cell sequencing. Tumor tissue specimens were collected from patients at different time points (before pretreatment, during CAR-T expansion, and at PD) and subjected to single-cell sequencing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06049381
Study type Observational
Source Ruijin Hospital
Contact Zixun Yan, Doctor
Phone +862164370045
Email yzx12119@rjh.com.cn
Status Not yet recruiting
Phase
Start date October 1, 2023
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05420493 - Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1
Recruiting NCT06026319 - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Phase 1
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Recruiting NCT06104592 - Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Phase 2
Recruiting NCT06158386 - Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma Phase 2
Recruiting NCT05826535 - Study of IMPT-314 in R/R Aggressive B-cell NHL Phase 1/Phase 2
Not yet recruiting NCT06343311 - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT04012892 - Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05621096 - Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Phase 1
Enrolling by invitation NCT05332054 - CB-Long-Term Safety Study (CB-LTSS)
Recruiting NCT05828589 - A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies Phase 1
Completed NCT02181478 - Intra-Osseous Co-Transplant of UCB and hMSC Early Phase 1
Not yet recruiting NCT06097455 - First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma Early Phase 1
Recruiting NCT05967416 - Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 1
Recruiting NCT05691153 - ThisCART19A for B-NHL Relapsed After Auto-CAR T Phase 1
Terminated NCT02875067 - Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma Phase 1/Phase 2
Not yet recruiting NCT05746858 - Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)